Verastem Oncology

Company

Also known as: Verastem Oncology

Related News

Artios expands leadership team as alnodesertib moves toward late-stage development

May 05, 2026

Artios added six senior leaders in 2026 as alnodesertib moved toward late-stage development and potential U.S. commercialization. The company is also running a Phase 2 study of ART6043.

Breast Cancer Research Advances: New Drug Trials and Resistance Mechanisms Identified

Mar 20, 2026

Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.